Disposition of the prodrug 4-(bis (2-chloroethyl) amino) benzoyl-L-glutamic acid and its active parent drug in mice. by Antoniw, P. et al.
Br. J. Cancer (1990), 62, 909-914
© Macmillan
Disposition of the prodrug 4-(bis (2-chloroethyl) amino)
benzoyl-L-glutamic acid and its active parent drug in mice
P. Antoniw, C.J. Springer, K.D. Bagshawe, F. Searle, R.G. Melton', G.T. Rogers, P.J. Burke
& R.F. Sherwood'
Cancer Research Campaign Laboratories, Department ofMedical Oncology, Charing Cross Hospital, London W6 8RF, UK; and
'PHLS Centrefor Applied Microbiology and Research, Division ofBiotechnology, Porton Down, Salisbury, Wilts. SP4 OJG, UK.
Sunmary A novel therapy for improving selectivity in cancer chemotherapy aims to modify distribution of a
cytotoxic drug by generating it selectively at tumour sites. In this approach an antibody-enzyme conjugate is
allowed to localise at the tumour sites before injecting a prodrug which is converted to an active drug
specifically by the targeted enzyme in the conjugate. We present here pharmacokinetic studies on the prodrug
4-(bis (2-chloroethyl) amino) benzoyl-L-glutamic acid and its activated derivative, benzoic acid mustard. The
glutamic acid is cleaved from the prodrug to form the active drug by carboxypeptidase G2 (CPG2), an enzyme
from Pseudomonas sp., which is not found in mammalian cells. The prodrug and its parent active drug were
rapidly distributed in plasma and tissues after administration of prodrug or active drug (41 tsmolkg-'
intraperitoneally) to mice bearing human choriocarcinoma xenografts. Prodrug and active drug both followed
a two-compartment kinetic model. Prodrug was eliminated more rapidly (t,/2 = 0.12 h, t,/2P= 0.70 h) than
active drug (t,/2a = 0.37 h, t,12P = 1.61 h). Conversion of the prodrug to the activated parent drug was detected
within 5 min of administration to mice which had previously received a F(ab')2-anti-human chorionic gonadot-
rophin antibody (W14A) conjugated to the enzyme, CPG2 (1,000 U kg-'). Tumour was the only tissue that
activated all the prodrug reaching the site. It contained the highest concentration of targeted enzyme conjugate
capable of catalysing the reaction of prodrug to drug. Plasma and other tissues were also capable of activating
the prodrug but active drug production was limited by the amount of enzyme present. The active drug
measured in plasma and tissues other than tumour was attributable to residual antibody-enzyme conjugate at
non-tumour sites. Low levels of conjugate in tissues and plasma militate against the advantage of tumour
localised enzyme therefore necessitating removal of non-localised enzyme.
The bioavailability of conventional cytotoxic drugs, like
other drugs, is generally determined by blood flow to target
sites and by their diffusion characteristics. This has not pro-
vided a satisfactory basis for selectivity against many cancers.
In order to achieve selective drug distribution the concept of
site specific activation of prodrugs was first explored in the
1950s. A series of azo mustards was designed and produced
by Ross and Warwick (1955) such that the azo link would be
cleaved by tumour enzymes in vivo, thus generating a power-
ful alkylating agent at the target site. Other compounds were
synthesised but they also required the presence of specific
tumour enzymes. Unfortunately, the activating enzymes were
not exclusively restricted to the tumours and thus the ap-
proach did not achieve selective action in humans. The
advent of monoclonal antibodies has opened the possibility
of conveying specific enzymes selectively to tumours thus
reviving the prodrug approach. A novel prodrug and an
antibody-enzyme conjugate for site-specific activation have
been reported (Bagshawe, 1987; Bagshawe et al., 1988). In
this paper we present pharmacokinetic data for xenograft
models using monoclonal antibodies directed at secreted
markers, carboxypeptidase G2 as the activating enzyme and
a benzoic acid mustard releasing prodrug.
The enzyme carboxypeptidase G2 (CPG2), isolated from
Pseudomonas (cloned and produced in E. coli), catalyses the
hydrolytic cleavage of reduced and non-reduced folates to
pteroates and L-glutamate (Sherwood et al., 1985). When
CPG2 is covalently linked to W14A, a monoclonal antibody to
human chorionic gonadotrophin, or to the F(ab')2 fragment
ment of W14A, both antibody and enzyme components
retain activity (Searle et al., 1986) and the conjugate localises
in choriocarcinoma xenografts (Melton et al., 1990). CPG2
also remains active when it is conjugated to A5B7, a mono-
clonal antibody to human carcinoembryonic antigen (Har-
wood et al., 1986; Pedley et al., 1987) or the F(ab')2 fragment
of A5B7, and the conjugate localises in the colon adenocar-
cinoma xenograft LS174T (Sharma et al., 1990). CPG2 is not
found in mammalian cells, neither is there any known mam-
malian homologue. Since there is no CPG2 in mammalian
cells, enzyme specific catalysis will occur only by admin-
istered conjugate. This two phase system has been termed
Antibody-Directed Enzyme Prodrug Therapy (ADEPT)
(Bagshawe, 1987).
The novel prodrug 4-(bis (2-chloroethyl) amino)benzoyl-L-
glutamic acid was synthesised by Springer et al. (1990). It is a
mustard glutamate prodrug (Figure 1) which has been
designed and shown to be activated by CPG2 to form the
active drug benzoic acid mustard (Bagshawe et al., 1988;
Springer et al., 1990).
Although there have been attempts to study the distribu-
tion of active drugs after site specific activation of prodrugs
by mathematical modelling (Smith- & Thijssen, 1986), no
experimental data have yet been published. In the studies
presented here, the plasma and tissue distribution of the
prodrug, the active drug and the activated prodrug derivative
generated in vivo have been determined.
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Figure I The prodrug 4-(bis (2-chloroethyl) amino) benzoyl-L-
glutamic acid and its benzoic acid mustard derivative, 4-(bis
(2-chloroethyl) amino) benzoic acid formed by cleavage of the
glutamic acid moiety by carboxypeptidase G2 (CPG2).
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Materials and methods
Tumour models andprotocols
Human CC3 choriocarcinoma (Searle et al., 1981) or LS174T
colon adenocarcinoma (Johnson et al., 1986) xenografts were
implanted into Nu/Nu mice. When the tumours were 0.5-
1.0 g, the mice were injected with antibody-enzyme con-
jugate (1,000 U kg-') intravenously. One unit of activity (U)
is defined as the amount of enzyme which catalyses the
hydrolysis of 1 pmol methotrexate per min per ml reaction
mixture at 37°C (Sherwood et al., 1985). After a period of
time to allow localisation (1-6 days), prodrug was injected at
two dose levels 16 mg kg-' or 160 mg kg-' intraperitoneally
(i.p.) or intravenously (i.v.). Prodrug was dissolved in
dimethyl sulphoxide/phosphate buffered saline (1:16). Pro-
drug and active drug were analysed in plasma and tissues by
HPLC.
Prodrug and active drug analysis procedure
Instrumentation and conditions HPLC analysis was perform-
ed using a Waters Assoc. system (UK). This consisted of a
Model 6000A solvent pump, a wisp 712 automatic injector,
and a model 480 variable wavelength UV detector, which
was set at 305 nm wavelength. Separation was performed on
a Waters C,8 jiBondapak cartridge (100 x 5 mm, 5;m parti-
cle size) with a guard column packed with pellicular C18
material. An isocratic mobile phase (35% acetonitrile/water
plus 1% acetic acid) was pumped at a constant flow rate
(1 ml min-'). The retention times of prodrug and active drug
were 5.8 and 13.9 min, respectively (Figures 2 and 3). Cali-
bration curves were constructed by addition of the prodrug
and active drug to plasma followed by extraction, prior to
HPLC. These are linear between 0.1-50fg ml-' (r>0.998).
The spectral analysis of the prodrug and active drug peaks
was carried out on a solution of standards in phosphate
buffered saline which was compared to the same peaks in an
extracted plasma sample (Figure 4). This analysis was carried
out using a Waters 490 multiwavelength detector. The
lambda max was identical for sample and standard: 320 nm
for prodrug and 310 nm for active drug.
Prodrug and active drug were stable compounds both in
organic solvents and aqueous solutions. The prodrug half life
was 26 h and active drug 10 h when a solution of each in
phosphate buffered saline (pH 7.4) was incubated at 37TC.
Two hydrolysis products were observed in each case with
short retention times (2.0 and 3.3 min in case of active drug,
and 1.9 and 2.5 min in case of prodrug; Figures 5 and 6).
Upon boiling in H2SO4 (0.1 N) or NaOH (0.1 N), both pro-
drug and active drug peaks disappeared and only the first
hydrolysis peak was visible in both cases.
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Figure 3 HPLC chromatograms of plasma extracts from mice
which had been administered with (a) prodrug, (b) active drug
and (c) W14-F(ab')2:CPG2 followed by prodrug 72 h later. Each
chromatogram represents a 201pI injection on to the HPLC col-
umn (peak 1: prodrug; peak 2: active drug).
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Figure 2 HPLC chromatogram of (a) control plasma extract
(40 id); (b) spiked phosphate buffer solution (40 gl), peak 1,
prodrug at 1.0igml-' and peak 2, active drug at 0.5figml-';
and (c) spiked plasma extract (40 gI), peak 1, prodrug at
l.Oygml-' and peak 2, active drug at 0.5jigml-'.
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Figure 4 Ultraviolet absorption spectra of prodrug and active
drug peaks in an extract of plasma obtained from nude mice
bearing CC3 choriocarcinoma xenografts, which received
antibody-enzyme conjugate followed by prodrug (sample). These
peaks were compared to the UV absorption spectra of prodrug
and active drug peaks in a standard solution in phosphate
buffered saline.
a
0.011
D
CL)
0
Mc 0.005-
-0
0 .n .0
<
r
1MUSTARD PRODRUG ACTIVATION BY LOCALISED CPG2 911
a
0.02-
a
C 0.01-
Co
L -.- -- - ~ ~---------
----------------
0.00 5 10 15 20 25
Time (minutes)
Figure 5 HPLC chromatogram ofprodrug (peak 1) incubated at
37°C in phosphate buffered saline, at 0 h (continuous line, a) and
24 h (dotted line, b) after incubation.
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Figure 6 HPLC chromatogram of active drug (peak 2)
incubated at 37°C in phosphate buffered saline, at 0 h (con-
tinuous line, a) and 24 h (dotted line, b).
Sample preparation and extraction Plasma and tissues were
prepared for HPLC analysis in the following manner. Mice
were anaesthetised using a halothane/N20/02 mixture. Blood
samples were obtained by cardiac puncture and tissues were
excised at different time intervals after drug administration.
Plasma (EDTA-K2 blood, Sarstedt) and excised tissues were
frozen at -70°C prior to analysis. No degradation of pro-
drug or active drug occurred during the storage period of up
to 3 months at -70°C. The tissues were sonicated (Heat
systems-ultrasonics) for 30-50 s to yield 10-20% homo-
genate in distilled water. Tissue homogenate (1 ml) or plasma
(0.25 ml) were used for drug analysis. Sodium dodecyl sul-
phate (SDS, 1 ml, 0.5%) was added to tissue homogenate to
aid the recovery of the compounds. The mixture was vor-
texed (15 s) and put through a pre-treated (1Oml methanol
and 10 ml 2 mM HCI) C,8 Sep-Pak (Waters Associates, UK).
The Sep-Pak was washed with HCI (4 ml, 2 mM) and the
prodrug and drug were eluted with methanol (3 ml). Samples
were dried in a Speedvac (Uniscience, UK) and the residues
were reconstituted in the HPLC mobile phase and injected
onto the HPLC. The plasma (0.25 ml) was added to HCI
(0.5 ml, 2 mM), vortexed, passed through the Sep-Pak and
then treated as described for the tissue samples. The extrac-
tion recoveries from plasma and tissues is 80-90% for pro-
drug and 90-95% for active drug. This difference in recovery
is reflected by larger standard errors for the prodrug
measurements when compared to those for the active drug
measurements.
Pharmacokinetic study. Pharmacokinetic parameters were
estimated using the interactive computer program, STRIPE
(Johnstone & Woolard, 1983). The data were entered as the
mean values for analysis. AUC from time 0 to the final time t
was estimated by the trapezoidal method. The remaining
AUC from t to infinity was estimated from the equation
AUC (t to infinity) = C,k-l, where C, is the blood concentra-
tion at t and k is the elimination rate constant given by the
slope of In plasma concentration versus time.
Plasmaprotein binding
Protein binding in plasma was measured in both mouse and
human plasma, using Centrifree micropartition filters
(Amicon, UK). Plasma (1 ml) was spiked with prodrug and
active drug to a final concentration of 2.5 tLg ml-'. The
plasma samples were centrifuged using a fixed angle rotor
(I h, 1,500g). The protein-free ultrafiltrate (0.25 ml) was ex-
tracted and analysed by HPLC, as described above. The
percentage of prodrug and active drug bound to plasma
proteins was determined by comparing the peak areas of the
plasma ultrafiltrate to that of the unfiltered samples.
Localisation ofantibody-enzyme conjugate
Four Nu/Nu mice bearing human CC3 choriocarcinoma
xenografts were injected i.v. with W14-F(ab')2: CPG2. After
56 h the animals were bled by cardiac puncture and tissues
were excised. Similarly five Nu/Nu mice bearing human
LS174T colon adenocarcinoma xenografts were injected i.v.
with A5B7-F(ab')2 CPG2 (1,000 U kg-'). These animals
were killed after 6 days. The conjugate A5B7-F(ab')2: CPG2
clears much more slowly from blood (Sharma et al., 1990)
than the W14-F(ab')2: CPG2 conjugate (Melton et al., 1990)
and it requires a delay of 6 days for blood conjugate levels to
drop sufficiently for the safe administration of the prodrug.
The different times and enzyme doses were chosen to mimic
those employed in a number of therapy experiments in order
to find out how much enzyme activity was present at the
tumour site when prodrug was being given for therapy.
Plasma and the excised tissues were kept at -70°C until
analysis. Trizma Base buffer (0.1 M, pH 7.3) containing ZnCl2
(0.2 mM) was added to the tissues and they were sonicated.
The tissue homogenate (1 ml) was incubated at 37°C with
prodrug to a final concentration of 34pgml-' (87 iM). The
reaction was stopped by addition of SDS (I ml, 0.5%). The
mixture was vortexed, centrifuged, passed through a Sep-Pak
and analysed by HPLC as described above. A standard curve
was constructed by measuring the amount of the active drug
generated from prodrug in vitro over time, using different
enzyme concentrations. The standard curve was used to
estimate the amount of enzyme present in the samples.
Results
Concentration vs time profiles for prodrug and active drug in
plasma and other tissues of nude mice bearing human CC3
choriocarcinoma xenografts are shown in Figure 7. Forty-one
pmolkg-' of either prodrug (equivalent to 16mgkg-') or
active drug (equivalent to 11 mg kg-') was injected i.p. Liver
had the highest concentration of the prodrug (62fig h g-1) and
the active drug (39ftg h g- '). The AUC values calculated from
concentration versus time profiles for tumour were 3.3jig h g-'
for prodrug and 8.5lighg-I for active drug. The pharma-
cokinetic parameters for prodrug and active drug in plasma
are summarised in Table I. In an independent experiment the
data for Figure 7b was reproduced between 0.5 h and 2 h after
injection of active drug (Table II).
Mice that received prodrug (16 mg kg-', 41 tmol kg-')
had measurable levels of active drug in plasma and tissues by
4 h after administration of prodrug. Liver had the highest
level (2.3 gg g-') followed by plasma (1.4 ig g-'). Active
drug was never measurable in the samples until 2h after
administration of prodrug and at 2 h not all the mice had912 P. ANTONIW et al.
detectable levels (Table III). Tumour had the lowest level of
active drug, which was not detectable at 2 h.
Prodrug and active drug were both significantly bound to
plasma proteins. In human plasma, prodrug was 92 ± 0.23%
( ± s.e.) and active drug 96 ± 0.07% bound. Similar results
were obtained with pooled mouse plasma, prodrug was
94± 0.67% and active drug 97 0.54% bound.
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Figure 7 Plasma and tissue distribution of (a) prodrug
(16 mg kg- 1,41 1smol kg-', i.p.), and (b) active drug (11 mg kg- ',
41 jlmol kg-', i.p.) in nude mice bearing human CC3 choriocar-
cinoma xenografts. Experimental points represent mean values
obtained from four mice per datum point. (-) plasma; (0) liver;
(0) lung; (A) kidney; (x) tumour. Standard error as percentage
of the mean varied from 7.3 to 40 for prodrug and from 1.0 to 18
for active drug.
Table I Plasma pharmacokinetics of the prodrug and the active
drug
AUC Vd
(llg h ml- I) (I)
Cl t,12c
(mlmin') (h)
Prodrug 7.09 0.07 1.18 0.12 0.75
Active drug 18.2 0.05 0.32 0.37 1.61
Mice bearing human CC3 choriocarcinoma xenografts were injected
i.p. with either the prodrug (16mg kg', 41 1smol kg-') or the active
drug (11 mg kg- , 41 1smol kg-'), respectively. AUC, area under
plasma concentration versus time curve from zero to infinity. Cl, total
body clearance. Vd, apparent volume of distribution. t,1/2, initial half
life. t1/2P, final half life.
Localisation of W14-F(ab')2: CPG2 and A5B7-F(ab')2:
CPG2 conjugates were studied in CC3 choriocarcinoma and
LS174T colon adenocarcinoma tumour models, respectively.
This was done by estimating the ability of the targeted tissue
to turn over prodrug to active drug in vitro. This method
demonstrated that the conjugate was localised at the tumour
site and retained its enzyme activity (Table IV). Tissues other
than tumour also had measurable enzyme activity. In the
CC3 model the level of enzyme in lung was 68% and kidney
12% of that of the tumour. In the LS174T model the enzyme
activity in lung was 21% and kidney 9.9% that of the
tumour. Tissues obtained from mice which did not receive
antibody-enzyme conjugate were also incubated with pro-
drug as above. No activation ofprodrug was observed in any
of the tissues.
Nude mice bearing human CC3 choriocarcinoma xeno-
grafts were injected i.v. with W14-F(ab')2: CPG2 (1,000 U
kg-1). After a period of localisation (72h) they received
prodrug (16mg kg-', 41 lmol kg-') i.v. Active drug was
measurable within 5 min of prodrug injection in all tissues
(Figure 8). It cleared from plasma in a biphasic manner.
Liver had the highest level of generated active drug (29 pg
h g-1). The plasma pharmacokinetic parameters are summar-
ised in Table V. The data for Figure 8 was reproduced in an
independent experiment between 0.5 h and 4.0 h after injec-
tion of the prodrug (Table VI). There was no measurable
Table II Plasma and tissue distribution of active drug (11 mg kg-,
41 pmol kg-, i.p.) in nude mice bearing human CC3 choriocarcinoma
xenografts
Active drug (i'g ml-' or jigg-') ±s.e.
Time (h)
Tissue 0.5 1.0 2.0
Plasma 5.63± 1.09 3.33±0.57 2.31±0.36
Liver 8.38± 1.23 3.76±0.65 2.97±0.48
Kidney 4.91 ±0.66 2.60±0.34 1.86±0.24
Lung 2.63±0.53 1.28±0.16 0.93±0.08
Tumour 1.43±0.42 1.03±0.20 1.09±0.09
Four mice were used per datum point.
Table III The active drug levels in the tissues ofmice bearing human
CC3 choriocarcinoma xenografts, after administration of prodrug
alone (16mg kg-', 41 iLmol kg-', i.p.)
Active drug (gLgml-' or jigg-1) ±s.e.
Time (h)
2 4
Plasma 0.30±0.15 1.40±0.05
Tumour 0.20±0.05
Liver 0.52±0.24 2.31±0.12
Lung 0.21 ±0.07 0.81 ±0.06
Kidney 0.29±0.11 1.25±0.09
Active drug was not measurable until 2 h after injection ofprodrug
and at 2 h not all the mice had detectable levels.
Table IV The enzyme activity present in the tissues of mice bearing
humanCC3 choriocarcinomaorLS174Tcolonadenocarcinoma xenog-
rafts
Enzyme(U) as % ofinjected dose g-' tissue±s.e.
Tissue W14-F(ab')2:CPG2 ASB7-F(ab')2:CPG2
Tumour 3.80±0.30 5.24±0.27
Lung 2.60±0.40 1.09±0.19
Kidney 0.45 ±0.03 0.52±0.03
Spleen 0.32±0.02 0.38±0.05
Muscle 0.12±0.04 0.16±0.07
Plasma 0.10±0.02 0.13±0.01
Liver 0.10±0.03 0.26±0.03
Brain 0.10±0.01 0.09±0.01
Gut 0.05±0.01 0.06±0.02
Mice received W14-F(ab')2:CPG2 (500 U kg-', i.v.) 56 h or
A5B7-F(ab')2:CPG2 (1,000 U kg-', i.v.), 6 days before excision of
tissues. Therewerenomeasurable levelsofenzyme activityin the tissues
or tumours ofcontrol mice that had not received the conjugate, in each
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Figure 8 Plasma and tissue concentration of the active drug
generated from the prodrug (16mg kg-', 41 imol kg', i.v.) in
vivo by localised antibody-enzyme conjugate (1,000 U kg-', i.v.).
Four nude mice bearing human CC3 choriocarcinoma xenografts
were used for each time point. (0) plasma; (0) liver; (0) lung;
(A) kidney; (x) tumour. Standard error as percentage of the
mean varied from 3.7 to 30.
unconverted prodrug present in the tumour. Tumour was the
only tissue that converted all the available prodrug to active
drug. The ratio of active drug generated to unconverted
prodrug for area under the curve of concentration vs time
plots in different tissues is shown in Table VII. Since prodrug
was not measurable in the tumour, for the purpose of cal-
culation the amount of prodrug present in the tumour was
assumed to be the limit of detection (0.2 jig h g-').
In the LS174T model (human colon adenocarcinoma xeno-
graft), using A5B7-F(ab')2: CPG2 conjugate, the peak levels
of generated active drug were compared to those in non-
tumour bearing nude mice. Both groups of animals received
the conjugate (1,000 U kg-') i.v., followed by prodrug
(160mg kg-', 410 jimol kg-') i.v., after 6 days. There was no
significant difference between active drug levels in plasma,
liver and lung in tumour bearing compared with non-tumour
bearing mice (Table VIII).
Table V Plasmapharmacokinetics ofthe prodrug and the active drug
in the mice bearing human CC3 choriocarcinoma xenografts after
administration ofW14-F(ab')2.CPG2 (1,000 U kg-', i.v.), followed by
prodrug (16mgkg-', 41ismol kg-', i.v.) 72 h later
AUC Vd Cl t,112 t,121
(gig h ml- ) (1) (mlmin-') (h) (h)
Prodrug 15.4 0.16 0.62 0.37 2.95
Active drug 20.5 0.11 0.46 0.37 2.71
See Table I for column headings.
TableVI Plasma and tissueconcentration oftheactivedruggenerated
from the prodrug (16 mg kg-' or 41 iLmol kg'-, i.v.) in vivo by localised
antibody enzyme conjugate (1,000 U kg-', i.v.)
Active drug (pgml-' or tgg-') ±s.e.
Time (h)
Tissue 0.5 1.0 2.0 4.0
Plasma 6.23± 1.45 3.35±0.43 1.94±0.86 1.18±0.44
Liver 5.85±0.29 3.83± 1.01 2.22±0.59 1.35±0.47
Kidney 3.75±0.52 3.17±0.49 1.85±0.20 1.15±0.16
Lung 2.65±0.50 1.32±0.17 0.80±0.10 0.68±0.17
Tumour 1.20±0.12 0.84±0.07 0.79±0.09 0.54±0.09
Four nude mice bearing human CC3 choriocarcinoma xenografts
were used for each time point.
Table VII The ratio of active drug (generated from prodrug) to
unconverted prodrug in each tissue
Tissue Ratio of AUCs
Tumour 29
Kidney 5.5
Liver 4.2
Lung 1.3
Plasma 0.9
Prodrug(16 mg kg-1,41 jamol kg-', i.v.) was administered 72 h after
W14-F(ab')2:CPG2 (1,000 U kg-', i.v).
Discussion
When prodrug and active drug were administered intraperi-
toneally (41 limol kg-'), they were rapidly distributed in the
plasma and tissues. Prodrug and active drug both followed a
two-compartment kinetic model. The biological t1/2 of pro-
drug (ax = 0.12 h, P = 0.7 h) was sufficiently long to allow
distribution of prodrug in all the tissues including the
tumour. However, the tl12 of the active drug (a = 0.37 h,
1= 1.61 h) may allow diffusion of active drug out of the
tumour into plasma and other tissues. A small amount of
active drug could be measured in plasma and tissues 4 h after
prodrug alone was administered to the mice. This activation
of prodrug was a very slow process and active drug was
never measurable until at least 2 h after injection of prodrug.
The levels were also much lower (plasma peak level = 0.72
gLgml-') when compared to active drug generated from pro-
Table VIII Plasmaand tissuelevels ofactivedrugafterinjectionofprodrug (160mgkg-',410pmolkg-',
i.v.) in tumour and non-tumour bearing mice
Active drug (;Lgm11 I or ;tgg- ) ±s.e.
Tumour bearing Non-tumour bearing
Time (min) Time (min)
5 15 30 5 15 30
Plasma 109.0±4.6 50.1±5.3 32.8±8.7 133.0±18.9 49.0±11.7 40.5±3.5
Liver 24.5±1.4 22.9±2.9 21.7±5.9 25.4±2.5 26.9±6.9 25.8±4.1
Lung 28.3±2.3 17.6±3.2 14.4±3.7 36.4±4.8 18.2±4.7 14.4± 1.5
Tumour 11.0± 1.7 10.3±1.8 11.5±2.4
BothgroupsofmicereceivedA5B7-F(ab')2:CPG2(1,000 U kg',i.v.)6daysbefore theprodrug. Adelay
of6dayswasrequired forantibody-enzymeconjugate toclearfromplasma. Iflessthan6dayswasallowed
before prodrug administration, mice died from non-localised active drugproduction. Four mice were used
per time point. The samples were not pooled but were analysed separately.914 P. ANTONIW et al.
drug in the presence of the conjugate (plasma peak level =
6.8fig ml-'; Bagshawe et al., 1988). The plasma protein bind-
ing was high for both prodrug (92%) and active drug (96%).
The antibody-enzyme conjugates W14-F(ab')2: CPG2
and A5B7-F(ab')2 :CPG2 were shown to localise preferen-
tially at the tumour site and to retain enzyme activity, for at
least 6 days. The distribution of these conjugates has been
studied previously by radiolabelling the enzyme and con-
jugating it to the fragmented antibody (Melton et al., 1990;
Sharma et al., 1990). The advantage of the novel method
described here is that a measure of the activity of the
localised enzyme is obtained.
When prodrug was given to nude mice bearing human
CC3 choriocarcinoma xenografts which had received anti-
body-enzyme conjugate 72 h earlier, active drug was detec-
table in plasma and tissues within 5 min. Although it was
shown that the tumour had the highest level of enzyme
activity, it did not have the highest level of active drug.
However, it was the only tissue that activated all the
available prodrug. A study of the prodrug distribution
(Figure 7a) demonstrated that tumour had the lowest level of
prodrug. The amount of active drug generated by tumour
was therefore limited by the amount of prodrug and not the
enzyme. From the results it appears that enzyme kinetics may
play an important role in relation to prodrug concentration
at the tumour site. The enzyme in plasma and tissues did not
activate all the prodrug received at these sites. This was
probably due to the relatively high levels of prodrug and low
levels of enzyme, since tumour located enzyme activated all
the available prodrug. This would indicate that it may be
possible to use larger doses of prodrug in order to achieve
greater production of active drug at tumour sites without
comparable enhancement of active drug production else-
where.
Further studies were undertaken in order to ascertain
whether the active drug found in non-tumour tissues was
produced at the tumour site and then released into plasma or
was due to the non-specific presence of the antibody-enzyme
conjugate in plasma and tissues, which led to activation of
prodrug at these sites. Mice bearing human LS174T colon
adenocarcinoma xenografts were compared with non-tumour
bearing nude mice. Both sets of mice received A5B7-F(ab')2:
CPG2, followed by prodrug 6 days later. The results, when
compared to the active drug levels expected in the absence of
conjugate, indicated that the presence of antibody-enzyme
conjugate at non-tumour sites was responsible for activation
of prodrug in plasma and other tissues. The enzyme has a
very high affinity for prodrug (Bagshawe et al., 1988) and
although the enzyme levels in tissues other than tumour and
lung were comparatively low, they were still capable of
activating prodrug.
It was shown previously that the prodrug 4-(bis (2-chloro-
ethyl) amino) benzoyl-L-glutamic acid had very little cytotox-
icity against the human JAR choriocarcinoma and LS174T
colonic cell lines in culture (Springer et al., 1990). On the
other hand the activated prodrug was over 100 times more
cytotoxic to JAR cells. It has also been shown previously
that although CC3 tumours have proved resistant to a wide
range of conventional cytotoxic agents, a marked inhibition
of growth of CC3 tumours in nude mice occurred with a
single course of treatment with the two phase prodrug
therapy described here (Bagshawe et al., 1988). In the present
study we have demonstrated that the prodrug is converted by
antibody-enzyme conjugate in vivo immediately to its active
derivative, benzoic acid mustard. The low concentration of
residual antibody-enzyme conjugate which remains in
plasma and tissues is able to activate the prodrug. This
observation confirms the need to confine enzyme activity to
tumour sites as rigorously as possible. A method of inacti-
vating enzyme in plasma without inactivating enzyme at
tumour sites has been developed in anticipation of these
findings (Bagshawe, 1989; Sharma et al., 1990).
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